Protara Therapeutics: Strategic Trial Shift and Strong Cash Runway Support Buy Rating Despite Price Target Cut to $20 From $26Tip Ranks·12 hours agoTARA-4.87%
Protara Therapeutics, Inc. 2Q 2026: Net income $(21.7) M, EPS $(0.36) — 10-Q SummaryTradingView·22 hours agoTARA-4.87%
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business UpdateUnusual Whales·23 hours agoTARA-4.87%
Protara Therapeutics CEO Jesse Shefferman disposes of 215,687 common shares for $882,156.83PUBT·Jul 1 at 03:11 PMTARA-4.87%
Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Studybenzinga_article·May 15 at 10:36 AMTARA-4.87%SBIO-0.03%
Oppenheimer Keeps Their Buy Rating on Protara Therapeutics (TARA)Tip Ranks·May 14 at 09:06 AMTARA-4.87%IBBQ-0.15%
